Allergan integrates Juvederm supplier
This article was originally published in The Gray Sheet
Executive Summary
Allergan will pay $216 mil. to acquire French firm Groupe Corneal Laboratoires - supplier of the firm's Juvederm next-generation hyaluronic acid dermal filler products - under a Nov. 1 agreement. Allergan, which previously held exclusive marketing rights to Juvederm and future product line extensions in the U.S., Canada and Australia, now gains exclusive rights to the technology worldwide. The deal also gives the firm control over future development and manufacturing of Juvederm and related hyaluronic acid dermal fillers. Allergan gained its initial rights to the injectable facial wrinkle treatment via its March purchase of aesthetic device maker Inamed and plans a January 2007 launch following FDA approval in June (1"The Gray Sheet" June 12, 2006, p. 15). The GCL deal is expected to close in the first quarter of 2007. Drug and device maker Allergan reported Q3 device sales of $116.3 mil. - all from Inamed - representing 15% of its $791.7 mil, in corporate sales...
You may also be interested in...
Allergan’s Juvederm Dermal Filler Approved, But Market Will Wait
Although Allergan's Juvederm dermal filler was approved by FDA ahead of schedule, the firm does not plan to market the cosmetic device immediately
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.